Gain Therapeutics, Inc.
NASDAQ:GANXBiotechnology
+$0.06 today
- Market cap
- $50.33M
- Beta
- 0.16
- P/E (TTM)
- -3.6
- EPS (TTM)
- -$0.50
Volume 4.26M
Average 0.64M
GANX Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
Gain Therapeutics, Inc.NASDAQ: GANX
Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Financing cash flow dips below year-ago levels
Q1 FY2026 financing cash flow of $404.32K fell 83.1% year over year, behind the +70.1% change in trailing-twelve-month financing cash flow. Sequentially, it fell 97.6% from the prior quarter.
Context
- Financing cash flow increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -83.1% toward the trailing-twelve-month pace of +70.1%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 28.45M USD
- Year-over-year change
- +118.6%
- 4-year CAGR
- -9.2%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 28.45M | +118.6% |
| FY2024 | 2024-12-31 | 13.01M | +2.9% |
| FY2023 | 2023-12-31 | 12.64M | +16147.6% |
| FY2022 | 2022-12-31 | (78.77K) | -100.2% |
| FY2021 | 2021-12-31 | 41.77M | — |
Financing Cash Flow vs competitors
How GANX compares with its peers on the latest reported figures
- GANX's LTM Mar 2026 financing cash flow of $26.46M is the 2nd largest of the 9 companies compared; the peer median is $2.8M.
- Its year-over-year change of +70.1% is the 4th highest of 8, against a peer median of +27.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $75.28M | +53361.2% | +21.9% | — | |
| LTM Mar 2026 | $26.46M | +70.1% | — | — | |
| LTM Mar 2026 | $19.12M | +27.6% | -10.3% | 833.6% | |
OSTXOS Therapies Incorporated | LTM Mar 2026 | $13.6M | +3.6% | +1272.4% | — |
| LTM Apr 2026 | $5.4M | +3417.5% | +223.2% | 299.7% | |
| LTM Jun 2024 | $2.15M | — | -37.1% | 264.1% | |
| LTM Mar 2026 | $2.09M | -102.2% | +0.9% | 3.2% | |
| LTM Mar 2026 | $189K | -99.9% | — | 2.1% | |
| LTM Mar 2026 | $0 | +100.0% | — | — | |
| Peer median (excluding GANX) | $2.8M | +27.6% | +11.4% | 264.1% | |
Competitors are the stored peer set for GANX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (13.89M) | (17.59M) | (22.27M) | (20.41M) | (20.16M) |
| Depreciation & Amortization | 15.48K | 64.17K | 83.58K | 84.07K | 94.05K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 839.37K | 1.53M | 3.26M | 2.39M | 1.8M |
| Change in Working Capital | (329.78K) | 1.51M | 442.23K | (1.08M) | (1.01M) |
| Accounts Receivables | (63.35K) | 3.63K | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (521.39K) | 1.07M | (643.16K) | 274.89K | (468.61K) |
| Other Working Capital | 254.96K | 444.52K | 1.09M | (1.36M) | (537.91K) |
| Other Non-Cash Items | 999.87K | (206.86K) | (383.19K) | 143.52K | 804.94K |
| Operating Cash Flow | (12.37M) | (14.69M) | (18.87M) | (18.87M) | (18.47M) |
| Capital Expenditures | (94.21K) | (118.95K) | (15.36K) | (22.49K) | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | (17.74M) | (1.96M) | 0 | 0 |
| Sales of Investments | 0 | 3.08M | 12.19M | 5M | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (94.21K) | (14.77M) | 10.22M | 4.98M | 0 |
| Debt Repayment | (21.95K) | (78.77K) | (89.07K) | (90.88K) | (96.5K) |
| Common Stock Issued | 42.63M | 0 | 12.73M | 13.21M | 28.54M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (841.27K) | 0 | 0 | (109.36K) | 0 |
| Financing Cash Flow | 41.77M | (78.77K) | 12.64M | 13.01M | 28.45M |
| Effect of Forex Changes | 100.78K | (23.8K) | 488.4K | (527.17K) | 469.43K |
| Net Change in Cash | 29.41M | (29.57M) | 4.49M | (1.41M) | 10.46M |
| Free Cash Flow | (12.46M) | (14.81M) | (18.88M) | (18.9M) | (18.47M) |
Gain Therapeutics, Inc.
NASDAQ:GANX
Intrinsic Alpha fair value
Locked
Current Price
$1.18
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.